Pre-market opportunity Eximis Surgical is in the pre-market phase with an FDA submission underway for its first device, indicating a high potential for early engagement with the company on regulatory strategy, clinical trial planning, and KOL collaboration to accelerate market entry.

Financing momentum Recent financing of 8.7M in 2023 led by Questa Capital with Olympus participation signals strong investor confidence and potential for strategic partnerships, offering angles for co-development discussions, validation studies, and scaled manufacturing discussions.

Automated RF platform The company’s automated, contained RF energy system for larger tissue specimen removal positions it to address high-cost, complex MIS procedures; identify hospitals or surgeons focusing on complex resections who seek safer, less invasive options.

Target market fit With a small but focused team (11-50 employees) and a Louisville, CO base, there may be capacity to partner on pilot programs, clinical sites, and reimbursement strategy development in the U.S., leveraging early adopters in mid-sized surgical centers.

Competitive landscape Similar players include EndoGastric Solutions, XACT Robotics, and NICO; positioning opportunities exist to differentiate on automated containment, large-specimen handling, and streamlined adoption pathways, while exploring co-marketing with Olympus Innovation Ventures to expand credibility.